Report

Version of Safety Report ID3Safety Report ID10489253primarysourcecountryJPoccurcountryJPtransmissiondateformat102transmissiondate28/05/2015reporttype1serious1seriousnessdeath1seriousnesshospitalization1seriousnessother1receivedateformat102Date Received02/10/2014receiptdateformat102Date Last Updated09/12/2014fulfillexpeditecriteria2companynumbJP-JNJFOC-20140924412duplicate1

Report Duplicate

duplicatesourceJANSSENduplicatenumbJP-JNJFOC-20140924412

Primary Source

reportercountryJPqualification1

Sender

sendertype2senderorganizationFDA-Public Use

Receiver

receivertype6receiverorganizationFDA

Patient

Onset Age41Unit of Onset Ageyearspatientagegroup5SexMale

Reaction

1)

reactionmeddraversionpt18.0ReactionDeathOutcomeFatal

2)

reactionmeddraversionpt18.0ReactionDepressed moodOutcomeUnknown

3)

reactionmeddraversionpt18.0ReactionHaemorrhageOutcomeUnknown

4)

reactionmeddraversionpt18.0ReactionAspirationOutcomeUnknown

5)

reactionmeddraversionpt18.0ReactionContusionOutcomeUnknown

6)

reactionmeddraversionpt18.0ReactionRoad traffic accidentOutcomeUnknown

7)

reactionmeddraversionpt18.0ReactionFallOutcomeUnknown

Drug

1)

drugcharacterization1medicinalproductLUNESTAdrugstructuredosagenumb3drugstructuredosageunit003drugseparatedosagenumb1drugintervaldosageunitnumb1drugintervaldosagedefinition804drugdosageformTABLETSdrugadministrationroute048drugindicationINSOMNIAdrugstartdateformat102drugstartdate31/07/2013

activesubstance

activesubstancenameESZOPICLONE

openFDA Info on Medication

Application NumberNDA021476Brand NameLUNESTAGeneric NameESZOPICLONEManufacturersSunovion Pharmaceuticals Inc.product_ndc63402-190, 63402-191, 63402-193Product TypeHUMAN PRESCRIPTION DRUGRouteORALActive IngredientsESZOPICLONERXCUI485440, 485442, 485465, 540407, 540409, 540411spl_id4c2704d7-3027-4240-9073-3f0b24cf15b5spl_set_idfd047b2b-05a6-4d99-95cb-955f14bf329fPackage NDC 63402-190-30, 63402-191-03, 63402-191-10, 63402-191-01, 63402-191-30, 63402-193- ... UNIIUZX80K71OE

2)

drugcharacterization1medicinalproductLEVOTOMINdrugstructuredosagenumb25drugstructuredosageunit003drugseparatedosagenumb2drugintervaldosageunitnumb1drugintervaldosagedefinition804drugdosageformTABLETdrugadministrationroute048drugindicationSCHIZOPHRENIAdrugstartdateformat102drugstartdate17/09/2014drugenddateformat102drugenddate21/09/2014

activesubstance

activesubstancenameLEVOMEPROMAZINE

3)

drugcharacterization1medicinalproductLEVOTOMINdrugstructuredosagenumb10drugstructuredosageunit003drugseparatedosagenumb1drugintervaldosageunitnumb1drugintervaldosagedefinition804drugdosageformTABLETdrugadministrationroute048drugindicationSCHIZOPHRENIAdrugstartdateformat102drugstartdate18/12/2013

activesubstance

activesubstancenameLEVOMEPROMAZINE

4)

drugcharacterization1medicinalproductLEVOTOMINdrugstructuredosagenumb15drugstructuredosageunit003drugseparatedosagenumb1drugintervaldosageunitnumb1drugintervaldosagedefinition804drugdosagetextAS AND WHEN NECESSARY (P.R.N)drugdosageformTABLETdrugadministrationroute048drugindicationINSOMNIAdrugenddateformat102drugenddate17/09/2014

activesubstance

activesubstancenameLEVOMEPROMAZINE

5)

drugcharacterization1medicinalproductZYPREXAdrugstructuredosagenumb20drugstructuredosageunit003drugseparatedosagenumb1drugintervaldosageunitnumb1drugintervaldosagedefinition804drugdosageformTABLETdrugadministrationroute048drugindicationSCHIZOPHRENIAdrugstartdateformat102drugstartdate25/09/2013drugenddateformat102drugenddate16/09/2014

activesubstance

activesubstancenameOLANZAPINE

openFDA Info on Medication

Application NumberNDA020592, NDA021086, NDA021253, NDA022173Brand NameZYPREXA, ZYPREXA ZYDIS, ZYPREXA INTRAMUSCULAR, ZYPREXA RELPREVVGeneric NameOLANZAPINE, OLANZAPINE PAMOATEManufacturersEli Lilly and Companyproduct_ndc 0002-4112, 0002-4115, 0002-4116, 0002-4117, 0002-4415, 0002-4420, 0002-4453, 000 ... Product TypeHUMAN PRESCRIPTION DRUGRouteORAL, INTRAMUSCULARActive IngredientsOLANZAPINERXCUI 153046, 153047, 153048, 200034, 212405, 261337, 283639, 284514, 312076, 312077, ... spl_id7184cd07-6f72-4413-9d11-daa74ef14b03, b222aade-353e-401c-b7d4-cb0da936e374spl_set_idd5051fbc-846b-4946-82df-341fb1216341, f9a73185-88de-4d7b-b3c0-bbf231483241Package NDC 0002-4112-30, 0002-4115-30, 0002-4116-30, 0002-4117-30, 0002-4415-30, 0002-4420- ... NUIN0000175430Established Pharmacologic ClassAtypical Antipsychotic [EPC]UNIIN7U69T4SZR

6)

drugcharacterization1medicinalproductEVAMYLdrugstructuredosagenumb2drugstructuredosageunit003drugseparatedosagenumb1drugintervaldosageunitnumb1drugintervaldosagedefinition804drugdosageformTABLETSdrugadministrationroute048drugindicationINSOMNIAdrugstartdateformat102drugstartdate06/06/2012

activesubstance

activesubstancenameLORMETAZEPAM

7)

drugcharacterization1medicinalproductLEVOTOMINdrugstructuredosagenumb25drugstructuredosageunit003drugseparatedosagenumb2drugintervaldosageunitnumb1drugintervaldosagedefinition804drugdosageformTABLETdrugadministrationroute048drugindicationINSOMNIAdrugstartdateformat102drugstartdate17/09/2014drugenddateformat102drugenddate21/09/2014

activesubstance

activesubstancenameLEVOMEPROMAZINE

8)

drugcharacterization1medicinalproductLEVOTOMINdrugstructuredosagenumb10drugstructuredosageunit003drugseparatedosagenumb1drugintervaldosageunitnumb1drugintervaldosagedefinition804drugdosageformTABLETdrugadministrationroute048drugindicationINSOMNIAdrugstartdateformat102drugstartdate18/12/2013

activesubstance

activesubstancenameLEVOMEPROMAZINE

9)

drugcharacterization1medicinalproductRILMAZAFONEdrugstructuredosagenumb4drugstructuredosageunit003drugseparatedosagenumb1drugintervaldosageunitnumb1drugintervaldosagedefinition804drugdosageformTABLETdrugadministrationroute048drugindicationINSOMNIAdrugstartdateformat102drugstartdate11/09/2013drugenddateformat102drugenddate21/09/2014

activesubstance

activesubstancenameRILMAZAFONE

10)

drugcharacterization1medicinalproductZYPREXAdrugstructuredosagenumb10drugstructuredosageunit003drugseparatedosagenumb1drugintervaldosageunitnumb1drugintervaldosagedefinition804drugdosageformTABLETdrugadministrationroute048drugindicationSCHIZOPHRENIAdrugstartdateformat102drugstartdate17/09/2014drugenddateformat102drugenddate21/09/2014

activesubstance

activesubstancenameOLANZAPINE

openFDA Info on Medication

11)

drugcharacterization1medicinalproductNITRAZEPAMdrugstructuredosagenumb20drugstructuredosageunit003drugseparatedosagenumb1drugintervaldosageunitnumb1drugintervaldosagedefinition804drugdosageformTABLETdrugadministrationroute048drugindicationINSOMNIAdrugstartdateformat102drugstartdate13/02/2013drugenddateformat102drugenddate21/09/2014

activesubstance

activesubstancenameNITRAZEPAM

12)

drugcharacterization1medicinalproductXEPLIONdrugbatchnumbDHB4M01drugauthorizationnumb022264drugstructuredosagenumb150drugstructuredosageunit003drugdosageformINJECTIONdrugadministrationroute030drugindicationSCHIZOPHRENIAdrugstartdateformat102drugstartdate17/09/2014drugrecurreadministration2

activesubstance

activesubstancenamePALIPERIDONE PALMITATE

13)

drugcharacterization1medicinalproductXEPLIONdrugbatchnumbDHB4M01drugstructuredosagenumb100drugstructuredosageunit003drugdosageformINJECTIONdrugadministrationroute030drugindicationSCHIZOPHRENIAdrugstartdateformat102drugstartdate08/01/2014drugenddateformat102drugenddate16/09/2014drugrecurreadministration2

activesubstance

activesubstancenamePALIPERIDONE PALMITATE

14)

activesubstance

activesubstancenameLEVOMEPROMAZINE

15)

drugcharacterization1medicinalproductROZEREMdrugstructuredosagenumb8drugstructuredosageunit003drugseparatedosagenumb1drugintervaldosageunitnumb1drugintervaldosagedefinition804drugdosageformTABLETdrugadministrationroute048drugindicationINSOMNIAdrugstartdateformat102drugstartdate05/03/2014drugenddateformat102drugenddate21/09/2014

activesubstance

activesubstancenameRAMELTEON

openFDA Info on Medication

Application NumberNDA021782Brand NameROZEREMGeneric NameRAMELTEONManufacturersTakeda Pharmaceuticals America, Inc.product_ndc64764-805Product TypeHUMAN PRESCRIPTION DRUGRouteORALActive IngredientsRAMELTEONRXCUI577348, 603162spl_idab007fde-2fd9-4b4c-9b1a-39b9e3e2fe0bspl_set_id9de82310-70e8-47b9-b1fc-6c6848b99455Package NDC64764-805-30, 64764-805-10, 64764-805-22NUIN0000175743, N0000000250Established Pharmacologic ClassMelatonin Receptor Agonist [EPC]Mechanism of ActionMelatonin Receptor Agonists [MoA]UNII901AS54I69

16)

drugcharacterization1medicinalproductQUAZEPAM.drugstructuredosagenumb30drugstructuredosageunit003drugseparatedosagenumb1drugintervaldosageunitnumb1drugintervaldosagedefinition804drugdosageformTABLETdrugadministrationroute048drugindicationINSOMNIAdrugstartdateformat102drugstartdate13/03/2013drugenddateformat102drugenddate21/09/2014

activesubstance

activesubstancenameQUAZEPAM

openFDA Info on Medication

Application NumberNDA018708Brand NameQUAZEPAM, DORALGeneric NameQUAZEPAMManufacturersAtland Pharmaceuticals, LLC, Galt Pharmaceuticals, LLCproduct_ndc71993-265, 61825-165Product TypeHUMAN PRESCRIPTION DRUGRouteORALActive IngredientsQUAZEPAMRXCUI198183, 207889spl_idbaff9baa-f149-c7e9-e053-2995a90a4306, ba9a5b9e-7a98-5de2-e053-2995a90a43b9spl_set_idf7d63f3f-5303-48ab-bce2-35fd62c45799, 9727e8b4-14f1-451d-9630-84eabc772e42Package NDC71993-265-30, 71993-265-10, 61825-165-10, 61825-165-30NUIN0000175694, M0002356Established Pharmacologic ClassBenzodiazepine [EPC]Chemical StructureBenzodiazepines [CS]UNIIJF8V0828ZI

summary

narrativeincludeclinicalCASE EVENT DATE: 201409

Adverse Event Report

Report

Report Duplicate

Primary Source

Sender

Receiver

Patient

Reaction

1)

2)

3)

4)

5)

6)

7)

Drug

1)

activesubstance

openFDA Info on Medication

2)

activesubstance

3)

activesubstance

4)

activesubstance

5)

activesubstance

openFDA Info on Medication

6)

activesubstance

7)

activesubstance

8)

activesubstance

9)

activesubstance

10)

activesubstance

openFDA Info on Medication

11)

activesubstance

12)

activesubstance

13)

activesubstance

14)

activesubstance

15)

activesubstance

openFDA Info on Medication

16)

activesubstance

openFDA Info on Medication

summary

Media

Newsletter

Follow us

Connect with us